Zobrazeno 1 - 10
of 943
pro vyhledávání: '"developability"'
Autor:
Georgina B. Armstrong, Vidhi Shah, Paula Sanches, Mitul Patel, Ricky Casey, Craig Jamieson, Glenn A. Burley, William Lewis, Zahra Rattray
Publikováno v:
Computational and Structural Biotechnology Journal, Vol 23, Iss , Pp 2345-2357 (2024)
The formulation of high-concentration monoclonal antibody (mAb) solutions in low dose volumes for autoinjector devices poses challenges in manufacturability and patient administration due to elevated solution viscosity. Often many therapeutically pot
Externí odkaz:
https://doaj.org/article/e2daa594cd5d4ef1982943739d76cbeb
Autor:
Peter Slavny, Manjunath Hegde, Achim Doerner, Kothai Parthiban, John McCafferty, Stefan Zielonka, Rene Hoet
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
The evolving development landscape of biotherapeutics and their growing complexity from simple antibodies into bi- and multi-specific molecules necessitates sophisticated discovery and engineering platforms. This review focuses on mammalian display t
Externí odkaz:
https://doaj.org/article/5cdfdebb503e41e486ff999878723167
Publikováno v:
Frontiers in Drug Discovery, Vol 4 (2024)
Antibodies represent the largest class of biotherapeutics thanks to their high target specificity, binding affinity and versatility. Recent breakthroughs in Artificial Intelligence (AI) have enabled information-rich in silico representations of antib
Externí odkaz:
https://doaj.org/article/a0b6669d453d4d6fb2f9ee963c3a01ee
Autor:
Itzel Condado-Morales, Fabian Dingfelder, Isabel Waibel, Oliver M. Turnbull, Bhargav Patel, Zheng Cao, Jais Rose Bjelke, Susanne Nedergaard Grell, Anja Bennet, Alissa M. Hummer, Matthew I. J. Raybould, Charlotte M. Deane, Thomas Egebjerg, Nikolai Lorenzen, Paolo Arosio
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
Engineered antibody formats, such as antibody fragments and bispecifics, have the potential to offer improved therapeutic efficacy compared to traditional full-length monoclonal antibodies (mAbs). However, the translation of these non-natural molecul
Externí odkaz:
https://doaj.org/article/902ae4a0e4394deeb9b5cd245a0a3c88
Autor:
Alaa Amash, Gesa Volkers, Patrick Farber, Daniel Griffin, K. Shawn Davison, Allison Goodman, Raffi Tonikian, Aaron Yamniuk, Bryan Barnhart, Tim Jacobs
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
Bispecific antibodies (bsAb) and multispecific antibodies (msAb) encompass a diverse variety of formats that can concurrently bind multiple epitopes, unlocking mechanisms to address previously difficult-to-treat or incurable diseases. Early assessmen
Externí odkaz:
https://doaj.org/article/020fa653c746460f9979c68b5e356aea
Autor:
Fortunato Ferrara, Adeline Fanni, Andre A. R. Teixeira, Esteban Molina, Camila Leal-Lopes, Ashley DeAguero, Sara D’Angelo, M. Frank Erasmus, Laura Spector, Luis Antonio Rodriguez Carnero, Jianquan Li, Thomas J. Pohl, Nikolai Suslov, Klervi Desrumeaux, Conor McMahon, Sagar Kathuria, Andrew R. M. Bradbury
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
We previously described an in vitro single-chain fragment (scFv) library platform originally designed to generate antibodies with excellent developability properties. The platform design was based on the use of clinical antibodies as scaffolds into w
Externí odkaz:
https://doaj.org/article/08adf8bbba7940a8b4cc3c5378c32316
Autor:
Tushar Jain, Bianka Prinz, Alexander Marker, Alexander Michel, Katrin Reichel, Valerie Czepczor, Sylvie Klieber, Wei Sun, Sagar Kathuria, Sevim Oezguer Bruederle, Christian Lange, Lena Wahl, Charles Starr, Alessandro Masiero, Lindsay Avery
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
In vitro assessments for the prediction of pharmacokinetic (PK) behavior of biotherapeutics can help identify corresponding liabilities significantly earlier in the discovery timeline. This can minimize the need for extensive early in vivo PK charact
Externí odkaz:
https://doaj.org/article/38817983990a4fd685f565a20d0c4cd1
Autor:
Shuai Wang, Yanqiu Wang, Zhenzhen Li, Ye Hong, Zhaohui Wang, Jiteng Fan, Qiong Wang, Yuanjie Ge, Xiaofeng Zhao, Guangcun Cheng, Changyan Chen, Yadan Wu, Yayuan Fu
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
Precise measurement of the binding activity changes of therapeutic antibodies is important to determine the potential critical quality attributes (CQAs) in developability assessment at the early stage of antibody development. Here, we report a surfac
Externí odkaz:
https://doaj.org/article/19cb036bf9994ae38eb022d448f32c83
Autor:
Mark Hutchinson, Jeffrey A. Ruffolo, Nantaporn Haskins, Michael Iannotti, Giuliana Vozza, Tony Pham, Nurjahan Mehzabeen, Harini Shandilya, Keith Rickert, Rebecca Croasdale-Wood, Melissa Damschroder, Ying Fu, Andrew Dippel, Jeffrey J. Gray, Gilad Kaplan
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
Over the past two decades, therapeutic antibodies have emerged as a rapidly expanding domain within the field of biologics. In silico tools that can streamline the process of antibody discovery and optimization are critical to support a pipeline that
Externí odkaz:
https://doaj.org/article/fd2f8ba9525448dbbf68ca2c03eef55e
Autor:
Eliott Park, Saeed Izadi
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
In silico assessment of antibody developability during early lead candidate selection and optimization is of paramount importance, offering a rapid and material-free screening approach. However, the predictive power and reproducibility of such method
Externí odkaz:
https://doaj.org/article/eb65760186ba4c83a17db95cba9a86f0